Pfizer and venture firm Flagship Pioneering have joined forces to develop 10 new drug candidates using technologies from Flagship’s startup ecosystem, in a partnership model that represents a more strategic approach to linking drug makers with startups to hunt for new medicines. Under the agreement, both parties will jointly identify opportunities for creating new medicines, with Pfizer funding selected development programs and having the option to license or acquire the asset.
Join the Fight Against Chronic Pain: It’s Time for Breakthrough Legislation in Congress
Over the past 15 years, financial and administrative barriers – most notably step therapy mandates and prior authorization requirements – have repeatedly forced patients through
